Kelun-Biotech’s Phase III trial shows its antibody-drug conjugate plus pembrolizumab beats chemo‑immunotherapy in PD‑L1‑negative NSCLC, potentially reshaping first‑line lung‑cancer treatment
Executive summary: Kelun-Biotech announced that its Phase III OptiTROP-Lung06 trial achieved its primary endpoint, showing that sacituzumab tirumotecan (sac‑TMT) plus pembrolizumab outperformed the standard chemotherapy‑immunotherapy regimen in patients with PD‑L1‑negative non‑squamous NSCLC. The outcome could replace chemotherapy in the first‑line setting for a substantial lung‑cancer patient population, reducing demand for pemetrexed/platinum drugs and altering the competitive landscape for immunotherapy combos.
Who is involved: Kelun-Biotech (sponsor), Merck’s pembrolizumab (Keytruda), clinical investigators of the OptiTROP-Lung06 trial, and patients with PD‑L1‑negative non‑squamous NSCLC.
Likely next: Full data analysis will be prepared for presentation at medical conferences and for submission to regulatory agencies seeking approval of the sac‑TMT + pembrolizumab regimen.
The OptiTROP-Lung06 study met its primary endpoint, demonstrating that sac‑TMT combined with pembrolizumab provides a statistically significant improvement over the standard pemetrexed/platinum plus immunotherapy regimen. This positions Kelun-Biotech’s antibody‑drug conjugate as a credible alternative to chemotherapy in a large patient subgroup, which could shift treatment algorithms and affect sales of existing chemo agents. If the result holds in the full data set, the company is likely to move swiftly toward regulatory submissions, while competitors may accelerate similar ADC‑immunotherapy combinations.
Timeline
- — Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis (PR Newswire)
- — Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint (PR Newswire)
Analysis — what this means
Sectors affected
Historical parallels
- Immutep’s INSIGHT-003 trial reported positive overall survival data in first-line NSCLC (July 2026)
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped